Q-omics provides the consensus-scored MIR5591 profile across patient tissues and cancer cell-line models. MIR5591 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MIR5591 is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, MIR5591 RNA expression shows 9,198 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight LIHC, and COAD as cancer lineages where MIR5591 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5591 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5591 survival associations across molecular data types. MIR5591 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5591 RNA expression–survival associations across cancer types. High MIR5591 expression shows unfavorable associations in LIHC, STAD, LUSC, BRCA, SKCM and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .012). Together, the overview and detailed table identify LIHC as the clearest survival context for MIR5591 RNA expression.
This table summarizes MIR5591 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5591. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5591 shows lower tumor expression in LUAD and higher tumor expression in LIHC. The LIHC box plot shows higher MIR5591 RNA expression in tumor versus normal tissue (log2 FC = +0.263, t-test p = .011).
This table shows molecular features associated with MIR5591 in patient tissues and cancer cell lines. In patient samples, MIR5591 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
